25 June 2018 | News
This newest system by Medtronic features the company's most advanced SmartGuard technology and most accurate CGM - the Guardian Sensor 3.
Image credit- naturalblaze.com
Medtronic plc, the global leader in medical technology, recently announced that the U.S. Food and Drug Administration (FDA) has approved the use of the MiniMe 670G system in patients with type 1 diabetes seven years of age and older. This newest system by Medtronic features the company's most advanced SmartGuard technology and most accurate CGM - the Guardian Sensor 3 - which work together to automate the delivery of a personalized amount of basal insulin every five minutes based on sensor glucose values.
The system constantly self-adjusts to help avoid highs and lows, allowing patients to spend more Time in Range (the percentage of time spent in the optimal glycemic range of 70-180 mg/dL). FDA approval was based on positive results from a pediatric clinical trial, which demonstrated the safety of the MiniMed 670G system in this younger patient population.
In the pediatric clinical trial, there was an increase in Time in Range (70-180mg/dL) for sensor glucose values and a reduction in time spent in both hypoglycemia and hyperglycemia, which is compelling in light of the well-known challenges associated with maintaining stable glucose levels throughout the day and night in this younger age group.